| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.04 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.064 | 0.04 |
| mRNA | lomeguatrib | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |